(VRSK) Verisk Analytics - Overview
Stock: Analytics, Underwriting, Claims, Catastrophe, Insurance
| Risk 5d forecast | |
|---|---|
| Volatility | 36.3% |
| Relative Tail Risk | -7.00% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -2.03 |
| Alpha | -49.62 |
| Character TTM | |
|---|---|
| Beta | 0.290 |
| Beta Downside | 0.248 |
| Drawdowns 3y | |
|---|---|
| Max DD | 46.98% |
| CAGR/Max DD | -0.02 |
EPS (Earnings per Share)
Revenue
Description: VRSK Verisk Analytics February 11, 2026
Verisk Analytics, Inc. (NASDAQ: VRSK) delivers data-analytics and technology platforms across the insurance value chain, covering underwriting, claims, fraud detection, catastrophe modelling, and specialty-business management for both U.S. and international markets. Its portfolio spans underwriting forms, rating rules, loss-cost services, life-insurance workflow tools, real-time marketing decisioning, and end-to-end reinsurance solutions.
According to the company’s 2023 Form 10-K, Verisk generated $3.21 billion in revenue, up 6 % year-over-year, with an operating margin of 21 % and diluted EPS of $5.08 for the full year. In the first quarter of 2024, revenue grew 4 % sequentially to $822 million and EPS accelerated to $1.15, reflecting continued demand for its catastrophe-risk and underwriting analytics amid a 15 % rise in U.S. natural-disaster loss exposure reported by the National Oceanic and Atmospheric Administration. The broader insurtech sector is also benefitting from regulatory pressure for more granular risk assessment and from insurers’ accelerated digital transformation budgets, which the Deloitte 2024 Insurance Outlook estimates will increase technology spend by roughly 9 % annually through 2027.
For a deeper dive into how Verisk’s data assets compare with peers, you might explore ValueRay’s comparative analytics platform.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 921.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.18 > 0.02 and ΔFCF/TA -2.02 > 1.0 |
| NWC/Revenue: 14.40% < 20% (prev -8.59%; Δ 22.98% < -1%) |
| CFO/TA 0.22 > 3% & CFO 1.35b > Net Income 921.4m |
| Net Debt (2.78b) to EBITDA (1.66b): 1.68 < 3 |
| Current Ratio: 1.19 > 1.5 & < 3 |
| Outstanding Shares: last quarter (139.9m) vs 12m ago -1.80% < -2% |
| Gross Margin: 69.62% > 18% (prev 0.68%; Δ 6894 % > 0.5%) |
| Asset Turnover: 56.08% > 50% (prev 61.87%; Δ -5.80% > 0%) |
| Interest Coverage Ratio: 9.09 > 6 (EBITDA TTM 1.66b / Interest Expense TTM 148.5m) |
Altman Z'' 7.54
| A: 0.07 (Total Current Assets 2.70b - Total Current Liabilities 2.26b) / Total Assets 6.24b |
| B: 1.23 (Retained Earnings 7.68b / Total Assets 6.24b) |
| C: 0.25 (EBIT TTM 1.35b / Avg Total Assets 5.40b) |
| D: 1.33 (Book Value of Equity 7.78b / Total Liabilities 5.86b) |
| Altman-Z'' Score: 7.54 = AAA |
Beneish M -3.39
| DSRI: 0.77 (Receivables 436.8m/526.6m, Revenue 3.03b/2.82b) |
| GMI: 0.98 (GM 69.62% / 68.24%) |
| AQI: 0.77 (AQ_t 0.45 / AQ_t-1 0.59) |
| SGI: 1.07 (Revenue 3.03b / 2.82b) |
| TATA: -0.07 (NI 921.4m - CFO 1.35b) / TA 6.24b) |
| Beneish M-Score: -3.39 (Cap -4..+1) = AA |
What is the price of VRSK shares?
Over the past week, the price has changed by -11.96%, over one month by -24.62%, over three months by -20.25% and over the past year by -41.96%.
Is VRSK a buy, sell or hold?
- StrongBuy: 3
- Buy: 3
- Hold: 10
- Sell: 2
- StrongSell: 0
What are the forecasts/targets for the VRSK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 248.5 | 46.6% |
| Analysts Target Price | 248.5 | 46.6% |
| ValueRay Target Price | 159 | -6.2% |
VRSK Fundamental Data Overview February 11, 2026
P/E Forward = 23.0947
P/S = 8.2183
P/B = 66.2306
P/EG = 2.0809
Revenue TTM = 3.03b USD
EBIT TTM = 1.35b USD
EBITDA TTM = 1.66b USD
Long Term Debt = 3.21b USD (from longTermDebt, last quarter)
Short Term Debt = 1.52b USD (from shortTermDebt, last quarter)
Debt = 4.89b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.78b USD (from netDebt column, last quarter)
Enterprise Value = 27.68b USD (24.90b + Debt 4.89b - CCE 2.11b)
Interest Coverage Ratio = 9.09 (Ebit TTM 1.35b / Interest Expense TTM 148.5m)
EV/FCF = 24.81x (Enterprise Value 27.68b / FCF TTM 1.12b)
FCF Yield = 4.03% (FCF TTM 1.12b / Enterprise Value 27.68b)
FCF Margin = 36.83% (FCF TTM 1.12b / Revenue TTM 3.03b)
Net Margin = 30.41% (Net Income TTM 921.4m / Revenue TTM 3.03b)
Gross Margin = 69.62% ((Revenue TTM 3.03b - Cost of Revenue TTM 920.3m) / Revenue TTM)
Gross Margin QoQ = 70.13% (prev 70.30%)
Tobins Q-Ratio = 4.43 (Enterprise Value 27.68b / Total Assets 6.24b)
Interest Expense / Debt = 0.86% (Interest Expense 42.2m / Debt 4.89b)
Taxrate = 25.36% (76.6m / 302.1m)
NOPAT = 1.01b (EBIT 1.35b * (1 - 25.36%))
Current Ratio = 1.19 (Total Current Assets 2.70b / Total Current Liabilities 2.26b)
Debt / Equity = 12.98 (Debt 4.89b / totalStockholderEquity, last quarter 376.7m)
Debt / EBITDA = 1.68 (Net Debt 2.78b / EBITDA 1.66b)
Debt / FCF = 2.49 (Net Debt 2.78b / FCF TTM 1.12b)
Total Stockholder Equity = 227.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 17.05% (Net Income 921.4m / Total Assets 6.24b)
RoE = 404.3% (Net Income TTM 921.4m / Total Stockholder Equity 227.9m)
RoCE = 39.23% (EBIT 1.35b / Capital Employed (Equity 227.9m + L.T.Debt 3.21b))
RoIC = 25.92% (NOPAT 1.01b / Invested Capital 3.89b)
WACC = 5.94% (E(24.90b)/V(29.79b) * Re(6.98%) + D(4.89b)/V(29.79b) * Rd(0.86%) * (1-Tc(0.25)))
Discount Rate = 6.98% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -1.89%
[DCF Debug] Terminal Value 87.13% ; FCFF base≈1.03b ; Y1≈1.14b ; Y5≈1.48b
Fair Price DCF = 289.6 (EV 43.14b - Net Debt 2.78b = Equity 40.36b / Shares 139.4m; r=5.94% [WACC]; 5y FCF grow 12.29% → 2.90% )
EPS Correlation: -20.32 | EPS CAGR: -45.57% | SUE: -4.0 | # QB: 0
Revenue Correlation: 35.24 | Revenue CAGR: 0.08% | SUE: -1.49 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.84 | Chg30d=+0.017 | Revisions Net=+3 | Analysts=13
EPS next Year (2026-12-31): EPS=7.72 | Chg30d=+0.067 | Revisions Net=+3 | Growth EPS=+11.2% | Growth Revenue=+6.4%